326 related articles for article (PubMed ID: 33307872)
1. New insights into the clinical management of advanced gastrointestinal stromal tumors.
Italiano A
Expert Opin Pharmacother; 2021 Mar; 22(4):439-447. PubMed ID: 33307872
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
3. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
4. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Serrano C; Mariño-Enríquez A; Tao DL; Ketzer J; Eilers G; Zhu M; Yu C; Mannan AM; Rubin BP; Demetri GD; Raut CP; Presnell A; McKinley A; Heinrich MC; Czaplinski JT; Sicinska E; Bauer S; George S; Fletcher JA
Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
7. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
8. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
9. Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E; Grondine M; Bhavsar D; Barry E; Kettle JG; Reddy VP; Brown C; Wang H; Mettetal JT; Collins T; Adeyemi O; Overman R; Lawson D; Harmer AR; Reimer C; Drew L; Packer MJ; Cosulich S; Jones RD; Shao W; Wilson D; Guichard S; Fawell S; Anjum R
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32350132
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
11. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
12. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
[TBL] [Abstract][Full Text] [Related]
13. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
15. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
16. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
Lee DM; Sun A; Patil SS; Liu L; Rao AV; Trent PT; Ali AA; Liu C; Rausch JL; Presutti LD; Kaczorowski A; Schneider F; Amankulor NM; Shuda M; Duensing A
Sci Rep; 2022 May; 12(1):8275. PubMed ID: 35585158
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.
Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J
Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525
[TBL] [Abstract][Full Text] [Related]
18. The management of metastatic GIST: current standard and investigational therapeutics.
Kelly CM; Gutierrez Sainz L; Chi P
J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.
Huang WK; Wu CE; Wang SY; Chang CF; Chou WC; Chen JS; Yeh CN
Curr Treat Options Oncol; 2022 Sep; 23(9):1303-1319. PubMed ID: 35976553
[TBL] [Abstract][Full Text] [Related]
20. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]